Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1130 - 1134
Section II - La réalité clinique
DOI https://doi.org/10.1051/medsci/200925121130
Publié en ligne 15 décembre 2009
  1. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapies in preclinical studies. Cancer Res 2005; 65 : 671–80.
  2. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33 : S26–34.
  3. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105 : 3005–10.
  4. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24 : 2283–9.
  5. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12 : 540–7.
  6. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6 : 175–82.
  7. Cook-Bruns, R. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001; 61 : 58–66.
  8. Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther 2008; 8 : 1963–71.
  9. de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43 : 2046–51.
  10. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94 : 2217–24.
  11. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98 : 2819–26.
  12. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49 : 697–702.
  13. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355 : 1018–28.
  14. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7 : 622–32.
  15. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355 : 1018–28.
  16. Stebbings R, Findlay L, Edwards C, et al. Cytokine storm in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179 : 3325–31.
  17. Müller N, van den Brandt J, Odoardi F, et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 2008; 118 : 1405–16.
  18. Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003; 76 : 459–63.
  19. Johansson A, Erlandsson A, Eriksson D, et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002; 94 : 1306–13.
  20. Committee for medicinal products for human use. European Medecines Agency. Guideline on strategies to identify and mitigate risks for first in human clinical trials with investigational medicinal products. September 1st 2007. http://www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.